Literature DB >> 28031182

Does ruxolitinib prolong the survival of patients with myelofibrosis?

Francisco Cervantes1, Arturo Pereira2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28031182     DOI： 10.1182/blood-2016-11-731604

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  40 in total

Review 1.  Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant.

Authors:  Michael Byrne; Bipin Savani; Michael R Savona
Journal:  Ther Adv Hematol       Date:  2018-07-16

Review 2.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 3.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

Review 4.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 5.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

6.  Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Authors:  Aaron T Gerds; Tetsuzo Tauchi; Ellen Ritchie; Michael Deininger; Catriona Jamieson; Ruben Mesa; Mark Heaney; Norio Komatsu; Hironobu Minami; Yun Su; Naveed Shaik; Xiaoxi Zhang; Christine DiRienzo; Mirjana Zeremski; Geoffrey Chan; Moshe Talpaz
Journal:  Leuk Res       Date:  2019-02-28       Impact factor: 3.156

Review 7.  Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Authors:  Claire N Harrison; Donal P McLornan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Authors:  Prithviraj Bose; Mahesh Swaminathan; Naveen Pemmaraju; Alessandra Ferrajoli; Elias J Jabbour; Naval G Daver; Courtney D DiNardo; Yesid Alvarado; Musa Yilmaz; Julie Huynh-Lu; Wei Qiao; Xuemei Wang; Aurelio Matamoros; Lingsha Zhou; Sherry Pierce; Kurt D Schroeder; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2019-01-11

Review 9.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

Review 10.  Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Authors:  Minas P Economides; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.